NEULANDLAB vs PPLPHARMA: Stock Comparison
PIRAMAL PHARMA is the larger company by market capitalisation. NEULAND LAB shows a higher ROE, a higher dividend yield and faster revenue growth, while PIRAMAL PHARMA shows a lower P/E and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
NEULANDLAB leads 8; PPLPHARMA leads 3 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | NEULANDLAB | PPLPHARMA |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | NEULANDLAB | PPLPHARMA |
|---|---|---|
| Live Price | ₹19,280 | ₹230.78 |
| Day Change | -3.46% | -0.87% |
| Volume | 71,654 | 2.64 Cr |
| 52-Week High | ₹24,225 | ₹235.64 |
| 52-Week Low | ₹11,500 | ₹132.3 |
| Distance from 52W High | -20.41% | -2.06% |
Valuation
| Metric | NEULANDLAB | PPLPHARMA |
|---|---|---|
| Market Cap | ₹24,748 Cr | ₹30,701 Cr |
| P/E Ratio | 49.72x | 0x |
| P/B Ratio | 13.2x | 3.76x |
| EPS | ₹115.1 | ₹-0.52 |
| Book Value | ₹1,461.02 | ₹61.31 |
| Dividend Yield | 0.18% | 0% |
Growth
| Metric | NEULANDLAB | PPLPHARMA |
|---|---|---|
| Revenue Growth (TTM YoY) | 136.4% | -0.1% |
| EPS Growth (TTM YoY) | 664.4% | 0% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 0% | 0% |
Profitability & Leverage
| Metric | NEULANDLAB | PPLPHARMA |
|---|---|---|
| ROE | 19.46% | 8.6% |
| ROCE | 19.17% | 9.1% |
| Net Margin | 17.99% | -3.68% |
| Operating Margin | 25.29% | 20.01% |
| Debt to Equity | 0.11x | 0.09x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | NEULANDLAB | PPLPHARMA |
|---|---|---|
| Promoter Holding | 32.26%▼ 0.36 pp | 34.8% |
| FII Holding | 21.93%▲ 0.85 pp | 13.65%▲ 1.13 pp |
| DII Holding | 16.26%▼ 0.25 pp | 14.44%▼ 0.13 pp |
| Public Holding | 29.55%▼ 0.24 pp | 36.71%▼ 0.92 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: NEULAND LAB and PIRAMAL PHARMA.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.